Stay updated on Tivozanib vs Sorafenib in Refractory RCC Clinical Trial
Sign up to get notified when there's something new on the Tivozanib vs Sorafenib in Refractory RCC Clinical Trial page.

Latest updates to the Tivozanib vs Sorafenib in Refractory RCC Clinical Trial page
- Check4 days agoChange DetectedThe page revision stamp changed from v3.5.3 to v3.5.4, indicating a small patch or metadata update rather than a substantive change to the page content.SummaryDifference0.0%

- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedA new publication citation has been added to the Publications section: Beckermann KE, Asnis-Alibozek AG, Atkins MB, Escudier B, Hutson TE, Kasturi V, McDermott DF, Pal SK, Porta C, Rini BI, Verzoni E. Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial. Oncologist. 2024 Mar 4;29(3):254-262. doi: 10.1093/oncolo/oyad348. This update expands the study's literature references related to outcomes in relapsed/refractory RCC treated with tivozanib.SummaryDifference0.0%

- Check26 days agoChange DetectedThe page’s revision/version indicator has been updated from v3.5.2 to v3.5.3, reflecting a general site release without altering the underlying study information.SummaryDifference0.0%

- Check33 days agoChange DetectedRegional names Královéhradecký kraj and Olomoucký kraj were updated to Hradec Králové Region and Olomouc Region, respectively, with the corresponding addresses adjusted. The revision tag was updated to v3.5.2.SummaryDifference0.1%

- Check47 days agoChange DetectedAdded Padova, Italy, 35128 and removed Padua, Italy, 35128 from the locations list.SummaryDifference0.0%

- Check54 days agoChange DetectedNapoli, Italy, 80131 was replaced with Naples, Italy, 80131 in the locations section.SummaryDifference0.0%

Stay in the know with updates to Tivozanib vs Sorafenib in Refractory RCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tivozanib vs Sorafenib in Refractory RCC Clinical Trial page.